AbbVie (ABBV) fell ~4% on Wednesday as BNP Paribas argued that its immunology blockbuster Skyrizi could face competition from Icotyde, a newly approved plaque psoriasis pill developed by Johnson & ...
Johnson & Johnson said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to ...
The clearance is the first for an oral peptide that blocks IL-23, the target of popular medicines like Skyrizi and Tremfya. J ...
After strutting its stuff against blockbusters in three head-to-head psoriasis trials, UCB’s Bimzelx has conquered another ...
Johnson & Johnson and Protagonist Therapeutics are countering the swarm of injectable biologics that have long dominated the ...
Johnson & Johnson won U.S. approval for a daily psoriasis pill that rivals the benefits of injectable medicines and could ...
J&J’s Icotyde will take on AbbVie’s blockbuster injectable Skyrizi as analysts forecast a blockbuster future for the pill.
The company said the FDA approved Icotyde to treat moderate to severe plaque psoriasis in adults and pediatric patients 12 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results